Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda, Tri-I TDI Conclude Research Deal
October 4, 2013
- Number of MRs Down Slightly to 63,846 as of March 2013; Are We Entering an Age of Decline for MRs?
October 4, 2013
- Nichi-Iko, South Korean Biotech Firm Partner Up on Biosimilar Business
October 3, 2013
- Nihon Chouzai to Increase Its Generic Portfolio to 1,000 in 2 Years: President Mitsuhara
October 3, 2013
- Asahi Kasei Pharma, Vernalis Sign Joint Research Agreement for New Drug Discoveries for Autoimmune Diseases
October 3, 2013
- Kissei, JCR to Jointly Develop Nesp Biosimilar
October 2, 2013
- Another Administrative Action Taken Against MTPC on Medway Injection; 3rd in 4 Years
October 2, 2013
- US FDA Approves Brintellix for Treatment of MDD in Adults: Takeda, Lundbeck
October 2, 2013
- Asahi Kasei Pharma, Pfizer Japan Strike Copromotion Deal for Recomodulin
October 2, 2013
- Nichi-Iko to Take Over Astellas’s Shizuoka Plant Next April
October 1, 2013
- Takeda Files for Approval of Hib Vaccine in Japan
October 1, 2013
- Amgen Astellas BioPharma to Go on Stream Oct. 1; JV Chief Takahashi Eager to Make It a “Category Leader”
September 30, 2013
- Luseogliflozin in Domestic PIII Study Significantly Reduces HbA1c: Taisho Pharmaceutical
September 27, 2013
- Nippon Shinyaku, Fuji Pharma Launch Lunabell Tablets ULD
September 27, 2013
- Maruho to Turn Maeda Pharmaceutical into Subsidiary, Expand Production Capability
September 26, 2013
- 3 Pharma Groups Demand Permanent Introduction of Premium at CSIMC; Healthcare Rep Still Wary
September 26, 2013
- Merck, NCC Tie Up in Cancer Drug R&D for Asian Patients
September 26, 2013
- Cancer Pain Reliever E-fen Buccal Tablets Launched: Taiho, Teikoku Seiyaku
September 26, 2013
- Daiichi Sankyo Dogged by Renewed Quality Woes at Ranbaxy; FDA Mute on Details
September 26, 2013
- Pfizer Japan’s Termination of CMR Agreement a Setback for Quintiles
September 25, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…